Abstract Number: 0732 • ACR Convergence 2020
Changing Evidence over Time: Updated Meta-analysis Regarding Anti-TNF Efficacy in Childhood Chronic Uveitis
Background/Purpose: To summarize evidence regarding efficacy of anti-tumour necrosis factor-α (anti-TNFα) in childhood autoimmune chronic uveitis (cACU), refractory to common disease modifying antirheumatic drugs (DMARDs).Methods:…Abstract Number: 1164 • ACR Convergence 2020
Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients
Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by innate immune dysregulation resulting in systemic inflammation and variable organ-specific clinical manifestations. The Translational Autoinflammatory Disease Section…Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…Abstract Number: 1672 • ACR Convergence 2020
Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients
Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall…Abstract Number: 1691 • ACR Convergence 2020
Applied Geostatistics in Pediatric Rheumatology – Spatial Clustering of IgA Vasculitis
Background/Purpose: IgA vasculitis (IgAV) is the most common childhood vasculitis, which etiology seems to be related to the combination of genetic as well as environmental…Abstract Number: 0597 • ACR Convergence 2020
Telemedicine in Pediatric Rheumatology During COVID-19: The PR-COIN Experience
Background/Purpose: Healthcare teams were forced to rethink the way they practiced medicine during the COVID-19 pandemic. Many teams transitioned from conducting in-person visits to virtual…Abstract Number: 0733 • ACR Convergence 2020
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children. Although there…Abstract Number: 1165 • ACR Convergence 2020
Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease
Background/Purpose: Herpes zoster (HZ) is a known serious infectious complication in children with autoimmune/autoinflammatory disease and potentially exacerbated by immunomodulatory medications. Information on HZ burden…Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…Abstract Number: 1692 • ACR Convergence 2020
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare, granulomatous, chronic large-vessel vasculitis that involves mostly the aorta and its major branches with a high mortality…Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium
Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre
Background/Purpose: The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…Abstract Number: 133 • 2020 Pediatric Rheumatology Symposium
Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
Background/Purpose: In addition to traditional rheumatic diseases (TRDs), Pediatric Rheumatologists are often consulted on emerging rheumatic diseases (ERDs) such as autoimmune encephalitis, seronegative vasculitides, and…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 52
- Next Page »